In the conditions when the process of immunization of the elderly and employees in the Army and the education system continues in the country, the European Medicines Agency (EMA) confirmed yesterday that there is a connection between the “AstraZeneca” vaccine and blood clotting, but stressed that this consequence is very rare and the benefits of the vaccine still outweigh the risks.
The Committee for Pharmacovigilance of the EMA concluded that unusual blood clots were found after vaccination with “AstraZeneka”, but how this reaction occurs is not clear.
The agency will inform all health workers how to detect blood clots in patients, while the warnings in the “AstraZeneka” instruction will be updated and will contain blood clots as a possible consequence of this vaccine.
